NO20042166L - Combination therapy for the treatment of disease - Google Patents

Combination therapy for the treatment of disease

Info

Publication number
NO20042166L
NO20042166L NO20042166A NO20042166A NO20042166L NO 20042166 L NO20042166 L NO 20042166L NO 20042166 A NO20042166 A NO 20042166A NO 20042166 A NO20042166 A NO 20042166A NO 20042166 L NO20042166 L NO 20042166L
Authority
NO
Norway
Prior art keywords
disease
treatment
combination therapy
therapy
combination
Prior art date
Application number
NO20042166A
Other languages
Norwegian (no)
Inventor
Antoine A Noujaim
Christopher F Nicodemus
Birgit C Schultes
Original Assignee
Altarex Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altarex Medical Corp filed Critical Altarex Medical Corp
Publication of NO20042166L publication Critical patent/NO20042166L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20042166A 2001-10-26 2004-05-25 Combination therapy for the treatment of disease NO20042166L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33924001P 2001-10-26 2001-10-26
PCT/IB2002/005794 WO2003034977A2 (en) 2001-10-26 2002-10-28 Combination therapy for treating disease

Publications (1)

Publication Number Publication Date
NO20042166L true NO20042166L (en) 2004-05-25

Family

ID=23328122

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042166A NO20042166L (en) 2001-10-26 2004-05-25 Combination therapy for the treatment of disease

Country Status (9)

Country Link
AT (1) AT500649A1 (en)
AU (1) AU2002358246B2 (en)
CA (1) CA2464947C (en)
CH (1) CH696871A5 (en)
DE (1) DE10297379T5 (en)
ES (1) ES2304264A1 (en)
GB (1) GB2397018B (en)
NO (1) NO20042166L (en)
WO (1) WO2003034977A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
WO2008091643A2 (en) * 2007-01-23 2008-07-31 Altarex Medical Corp. In vitro culture system to evaluate synergy in targeting immune suppressive pathways concurrent to immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6997394A (en) * 1993-05-27 1994-12-20 Harald Schlebusch Monoclonal anti-idiotypic anti-ca125 antibodies and pharmaceutical compositions containing them
DK0910407T3 (en) * 1996-05-15 2003-06-16 Altarex Inc Method and composition for reconstitution of multiepitope antigens to initiate an immune response
WO2001000245A2 (en) * 1999-06-25 2001-01-04 Genentech, Inc. HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
AU5286999A (en) * 1999-07-23 2001-02-13 Glaxo Group Limited Combination of an anti-ep-cam antibody with a chemotherapeutic agent
JP2003519096A (en) * 1999-08-18 2003-06-17 アルタレックス コーポレーション Therapeutic antibodies to MUC-1 antigen and methods of using the same
TR200200472T2 (en) * 1999-08-27 2002-06-21 Genentech, Inc. Dosages for treatment with anti-Erb B2 antibodies
CA2399067A1 (en) * 2000-02-08 2001-08-16 Altarex Corp. Method for diagnosing efficacy of xenotypic antibody therapy
GB2390811B (en) * 2001-03-21 2006-01-18 Altarex Inc Therapeutic compositions that alter the immune response

Also Published As

Publication number Publication date
GB2397018A (en) 2004-07-14
WO2003034977A3 (en) 2004-05-27
ES2304264A1 (en) 2008-10-01
CA2464947A1 (en) 2003-05-01
WO2003034977A2 (en) 2003-05-01
AT500649A1 (en) 2006-02-15
DE10297379T5 (en) 2004-10-14
GB0409191D0 (en) 2004-05-26
CA2464947C (en) 2012-05-22
GB2397018B (en) 2006-05-31
AU2002358246B2 (en) 2008-02-28
CH696871A5 (en) 2008-01-15

Similar Documents

Publication Publication Date Title
CY2019030I2 (en) RAPAMYCIN DERIVATIVE FOR THE THERAPEUTIC TREATMENT OF LUNG CANCER
NO20053077D0 (en) Therapeutic formulations for the treatment of beta-amyloid-related diseases.
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
NO20041882L (en) Methods for the treatment of ocular neovascular diseases.
NO20052894D0 (en) 4-tetrazolyl-4-phenylpiperidine derivatives for the treatment of pain
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
NO20033594L (en) Phenethanolamine derivatives for the treatment of respiratory diseases
CY2014019I1 (en) PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES
DE60142473D1 (en) INTRAKORPORAL MEDICAMENTS FOR THE PHOTODYNAMIC TREATMENT OF ILLNESSES
NO20034590L (en) Procedures for the treatment of vascular disease
NO20026008L (en) Procedure for the treatment of cardiovascular diseases
NO20040516L (en) Combination therapy for the treatment of cancer.
NO20034780L (en) Combination antiangiogenic therapy for the treatment of cancer
NO20041386L (en) Combinations for the treatment of immuno-inflammatory disorders
NO20024775D0 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
DE60236743D1 (en) FOR THE TREATMENT OF ANDROGEN-DEPENDENT DISEASES
NO20034123L (en) Procedure for the treatment of fuel
NO20033804D0 (en) Carbamate compounds for the treatment of pain
NO20024777L (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
NO20024776D0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
NO20020784L (en) Medication for the treatment of fractures
NO20042476L (en) Use of desoxypeganine for the treatment of clinical depression
IL155237A0 (en) Combination therapy for the treatment of estrogen-sensitive disease
NO20043113L (en) Procedure for the treatment of bone disorder
NO20012612L (en) Isonipecotamides for the treatment of integrin-mediated diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application